Biomarker for Niemann Pick Type C Disease (BioNPC)
NCT01306604 · Status: WITHDRAWN · Type: OBSERVATIONAL
Last updated 2023-02-13
Summary
Development of a new MS-based biomarker for the early and sensitive diagnosis of Niemann Pick Type C disease from Blood (plasma)
Conditions
- Niemann-Pick Disease
- Niemann-Pick Disease, Type C
Sponsors & Collaborators
-
CENTOGENE GmbH Rostock
lead INDUSTRY
Principal Investigators
-
Peter Bauer, Prof. · Centogene GmbH
Eligibility
- Min Age
- 1 Day
- Sex
- ALL
- Healthy Volunteers
- No
Timeline & Regulatory
- Start
- 2018-08-20
- Primary Completion
- 2021-02-28
- Completion
- 2021-02-28
Countries
- Germany
- India
- Sri Lanka
Study Locations
More Related Trials
-
Muscular Biomarkers in Amyotrophic Lateral Sclerosis
NCT02670226 ·Status: COMPLETED ·Phase: NA
-
Biospecimen Biorepository for the Study of ALS, ALS-FTD and Similar Neurodegenerative Disorders
NCT05116943 ·Status: RECRUITING
-
A Longitudinal Study of Amyotrophic Lateral Sclerosis (ALS) Biomarkers
NCT01495390 ·Status: COMPLETED
-
Clinical Trial Readiness for the Dystroglycanopathies
NCT00313677 ·Status: RECRUITING
-
Cervical Spinal Cord Metabolism and Microstructure in Amyotrophic Lateral Sclerosis(ALS)
NCT02000713 ·Status: TERMINATED ·Phase: NA
-
Imaging and BioFluid Biomarkers in Amyotrophic Lateral Sclerosis
NCT02559869 ·Status: COMPLETED
-
Biomarker Development for Muscular Dystrophies
NCT05019625 ·Status: RECRUITING
-
Translating Single-cell Vulnerability Into Novel ALS Biomarkers and Therapeutic Targets: Towards a Liquid Nerve Biopsy
NCT07268833 ·Status: RECRUITING
-
Multimodal Imaging Outcome Measures for ALS (Image ALS)
NCT04490096 ·Status: TERMINATED ·Phase: PHASE1
-
Amyotrophic Lateral Sclerosis: A Multicenter Retrospective Observational Registry
NCT07143656 ·Status: ACTIVE_NOT_RECRUITING
-
Biomarker for Duchenne Muscular Dystrophy
NCT02994030 ·Status: COMPLETED
-
Determinants of Disease Severity in Amyotrophic Lateral Sclerosis
NCT00004457 ·Status: UNKNOWN
-
Establishment of a Tissue Bank (Blood, CSF) for the Understanding of Motor Neuron Disease (MND)
NCT01950910 ·Status: TERMINATED
-
Study of [11C]CPPC to Assess the Safety and Tolerability in Patients With ALS
NCT04749433 ·Status: TERMINATED ·Phase: PHASE1
-
Amyotrophic Lateral Sclerosis: a New Paradigm
NCT03073239 ·Status: COMPLETED
-
A Pilot Study of Biomarkers for Spinal Muscular Atrophy
NCT00756821 ·Status: COMPLETED
-
Imaging Biomarkers in ALS
NCT02567136 ·Status: RECRUITING
-
Skeletal Muscle Biomarkers in People With Fragile Sarcolemmal Muscular Dystrophy
NCT01851447 ·Status: ACTIVE_NOT_RECRUITING
-
Oligomeric Alpha-synuclein in Multiple System Atrophy
NCT01485549 ·Status: COMPLETED
-
Spinal Muscular Atrophy (SMA) Biomarkers Study in the Immediate Postnatal Period of Development
NCT01736553 ·Status: COMPLETED
-
3K3A-APC for Treatment of Amyotrophic Lateral Sclerosis (ALS)
NCT05039268 ·Status: COMPLETED ·Phase: PHASE2
-
Understanding Clinical Phenotype and Collecting Biomarker Samples in C9ORF72 ALS
NCT02686268 ·Status: COMPLETED
-
Research of Biomarkers in Duchenne Muscular Dystrophy Patients
NCT01380964 ·Status: COMPLETED
-
Patients With Congenital Myasthenic Syndrome Will be Treated With Mesenchymal Stem Cell Exosome Solution
NCT07226726 ·Status: RECRUITING ·Phase: PHASE1
-
An Open Label Phase 2 Study of ManNAc in Subjects With GNE Myopathy
NCT02346461 ·Status: COMPLETED ·Phase: PHASE2